Incentives for R&D for new antimicrobial drugs

International Journal of the Economics of Business

Volumn 18, Issue 2, 2011, Pages 331-350

  Towse, Adrian ^a   Sharma, Priya ^a  

^a Office of Health Economics   (United Kingdom)

Author keywords

Antibacterials; Antimicrobial resistance; Incentives; Net present value and europe; Research and development

Indexed keywords

EID: 79961157470     PISSN: 13571516     EISSN: 14661829     Source Type: Journal    
DOI: 10.1080/13571516.2011.584434     Document Type: Article

References (40)

1. Boucher, Helen, Talbot, George H., Bradley, John S., Edwards, John E., Gilbert, David, Rice, Louis B., Scheld, Michael, Spellberg, Brad, and Bartlett, John (2009) Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America, Clinical Infectious Diseases, 48, pp. 1-12.
2. Council of the European Union (2009) Council conclusions of 1 December 2009 on innovative incentives for effective antibiotics, Official Journal of the European Union, 52, C 302/05. Available at: http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:C:2009:302:0010:0011:EN:PDF [Accessed 2 April 2011].
3. Danzon, Patricia, and Towse, Adrian (2003) Differential pricing for pharmaceuticals: Reconciling access, R&D and patents, Journal of Health Care Financing and Economics, 3, pp. 183-205.
4. Danzon, Patricia, and Towse, Adrian (2002) The economics of gene therapy and of pharmacogenetics, Value in Health, 5, pp. 5-13.
5. DiMasi, Joseph A., Hansen, Ronald W., and Henry, G. (2003) The price of innovation: New estimates of drug development costs, Journal of Health Economics, 22, pp. 151-85.
6. ECDC (European Centre for Disease Prevention and Control) and EMEA (European Medicines Agency) (2009) The bacterial challenge: Time to react. Joint technical report (Stockholm: EMEA).
7. European Commission (2009) Part III: annexes to Impact Assessment Guidelines (Brussels: European Commission).
8. FDA (Food and Drug Administration) (2010) Draft guidance: the judicious use of medically important antimicrobial drugs in food-producing animals, Federal Register, 75(124), pp. 37450-37451. Available at: http://edocket.access.gpo.gov/2010/pdf/2010-15289.pdf [Accessed 2 April 2011].
9. Gilbert, D.N., et al. (2010) The 10x20 initiative: pursuing a global commitment to develop 10 new antibacterial drugs by 2020, Clinical Infectious Diseases, 50, pp. 1081-83.
10. Grabowski, Henry G. (2005) Encouraging the development of new vaccines, Health Affairs, 24, pp. 697-700.
11. Grabowski, Henry, Ridley, David, and Moe, Jeffrey (2008) Priority Review Vouchers to Encourage Innovation for Neglected Diseases (Durham: Duke University).
12. Guilloton, Sheila (2010) India denounces British report that superbug NDM-1 comes from India: Charges plot to malign India. Examiner.com, 13 August. Available at: http://www.examiner.com/health-care-in-national/india-denounces-british-report-that-superbug-ndm-1-comes-fromindia-charges-plot-to-malign-india?cid=parsely#parsely [Accessed 2 April 2011].
13. Harris, G. (2010) Antibiotics in animals need limits, FDA says, The New York Times, 29 June, pp. A15.
14. Herriman, Robert (2010) India health officials lash out at NDM-1 study, suggests "sinister design". Examiner.com, 15 August. Available at: http://www.examiner.com/infectious-disease-innational/india-health-officials-lash-out-at-ndm-1-study-suggests-sinister-design?cid=parsely#parsely [Accessed 2 April 2011].
15. HSUS (The Humane Society of the United States) (2007) An HSUS Report: Human Health Implications of Non-therapeutic Antibiotic Use in Animal Agriculture (Washington, DC: HSUS). Available at: http://www.humanesociety.org/assets/pdfs/farm/HSUS-Human-Health-Report-on-Antibioticsin-Animal-Agriculture.pdf [Accessed 2 April 2011].
16. Kaufmann, A.F., Meltzer, M.I., and Schmid, G.P. (1997) The economic impact of a bioterrorist attack: Are prevention and postattack intervention programs justifiable? Emerging Infectious Diseases, 3, pp. 83-94.
17. Kesselheim, Aaron S., and Outterson, Kevin (2010) Fighting antibiotic resistance: Marrying new financial incentives to meeting public health goals, Health Affairs, 29, pp. 1689-96.
18. Kesselheim, Aaron S., and Outterson, Kevin (2011) Improving antibiotic markets for long term sustainability, Journal of Health, Policy, Law and Ethics, 11.
19. Kremer, Michael (2001) Public policies to stimulate the development of vaccines and drugs for the neglected diseases. World Health Organisation Commission on Macroeconomics and Health. Working paper series. Paper no. WG2:7. Geneva: World Health Organisation.
20. Kumarasamy, K.K., et al. (2010) Emergence of a new antibiotic resistance mechanism in India, Pakistan and the UK: A molecular, biological, and epidemiological study, The Lancet Infectious Diseases, 10, pp. 597-601.
21. Laximinarayan, Ramana, and Brown, G. (2000) Economics of antibiotic resistance: A theory of optimal use? Discussion paper 00-36 (Washington, DC: Resources for the Future).
22. Laxminarayan, Ramana and Malani, A. (2007) Extending the cure: Policy responses to the growing threat of antibiotic resistance (Washington, DC: Resources for the Future).
23. Meltzer, M.I., Cox, N.J., and Fukuda, K. (1999) The economic impact of pandemic influenza in the United States: Priorities for intervention, Emerging Infectious Diseases, 5, pp. 659-71.
24. Moran, Mary (2005) A breakthrough in R&D for neglected diseases: New ways to get the drugs we need, PLoS Medicine, 2, pp. 828-32.
25. Mossialos, Elias, Morel, Chantal, Edwards, Suzanne, Berenson, Julia, Gemmill, Toyama Marin, and Brogan, David (2009) Policies and Incentives for Promoting Innovation in Antibiotic Research (London: London School of Economics and Political Science).
26. Nugent, Rachel, Pickett, Jessica, and Back, Emma (2008) Drug Resistance and a Global Health Policy Priority (Washington, DC: Center for Global Development).
27. Nugent, Rachel, Back, Emma, and Beith, Alexandra (2010) The Race Against Drug Resistance (Washington, DC: Center for Global Development).
28. Paul, S.M., et al. (2010) How to improve R&D productivity: The pharmaceutical industry's grand challenge, Nature Reviews Drug Discovery, 9, pp. 203-14.
29. Payne, D.J., Gwynn, M.N., Holmes, D.J., and Pompliano, D.L. (2007) Drugs for bad bugs: Confronting the challenges of antibacterial discovery, Nature Reviews Drug Discovery, 6, pp. 29-40.
30. Philipson, Tomas J. (2000) Economic epidemiology and infectious disease in: J. Newhouse and A. Culyer (Eds), Handbook of health economics (New York: North Holland Biomedical Press).
31. Philipson, Tomas J., Mechoulan, S., and Jena, Anupam (2006) Health Care, Technological Change and Altruistic Consumption Externalities. NBER Working Paper No. 11930 (Boston: National Bureau of Economic Research).
32. Philipson, Tomas J., and Mechoulan, Stephanie (2003) Intellectual property & external consumption effects: Generalisations from pharmaceutical markets. NBER Working Paper 9598 (Boston: National Bureau of Economic Research).
33. Power, E. (2006) Impact of antibiotic restrictions: The pharmaceutical perspective, Clinical Microbiology Infectious, 12, pp. 25-34.
34. Projan, S. (2003) Why is big pharma getting out of antibacterial drug discovery? Current Opinion in Microbiology, 6, pp. 427-30.
35. Ridley, D.B., and Sanchez, A.C. (2010) Introduction of European priority review vouchers to encourage development of new medicines for neglected diseases, The Lancet, 376, pp. 922-27.
36. Sharma, Priya, and Towse, Adrian (2011) New drugs to tackle antimicrobial resistance: Analysis of EU policy options. OHE Occasional Paper 10/01 (London: Office of Health Economics).
37. Shlaes, D.M., and Projan, S. (2009) Antimicrobial resistance versus the discovery and development of new antimicrobials, in: D. L. Mayers (Ed), Antimicrobial drug resistance: Mechanisms of drug resistance, volume 1 (New York: Humana Press), pp. 43-51.
38. Swedish Presidency of the European Union (2009) Innovative incentives for effective antibacterials. Available at: http://www.se2009.eu/en/meetings_news/2009/9/17/conference_innovative_incentives_for_effective_antibacterials.html [Accessed 2 April 2011].
39. Taubes, Gary (2008) The bacteria fight back, Science, 321, pp. 356-61.
40. World Health Organization (2004) The global burden of disease: 2004 update (Geneva: World Health Organization).